MorphoSys AG (MOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The companys pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used for the treatment of various types of cancers, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, solid tumors, eye disease, and other inflammatory diseases. Morphosys offers human combinatorial antibody library (HuCAL), a recombinant antibody technology which allows generation of therapeutic and diagnostic antibodies. The company provides clinical trials for cancer and inflammatory disorders. It also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products in China, Taiwan, Hong Kong, and Macao. Morphosys is headquartered in Munich, Germany.

MorphoSys AG (MOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MorphoSys AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Lanthio Pharma Raises US$6 Million In Series A Financing 13
Partnerships 14
MorphoSys Expands Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
Licensing Agreements 21
Novartis Pharma Enters into Licensing Agreement with Galapagos and MorphoSys 21
I-Mab Biopharma Enters into Licensing Agreement with MorphoSys 23
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 25
MorphoSys Enters into Licensing Agreement with Merck Serono 27
MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 28
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 30
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 31
Equity Offering 32
MorphoSys Raises USD239 Million in Public Offering of Shares 32
MorphoSys Raises USD124.3 Million in Private Placement of Shares 34
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 35
Acquisition 37
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 37
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys 38
MorphoSys AG - Key Competitors 39
MorphoSys AG - Key Employees 40
MorphoSys AG - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Aug 02, 2018: MorphoSys reports second quarter 2018 financial results 42
May 02, 2018: MorphoSy Reports First Quarter 2018 Results 44
Mar 13, 2018: MorphoSys Presents Results for Fiscal Year 2017 46
Nov 07, 2017: MorphoSys Announces Third Quarter 2017 Results 49
Aug 03, 2017: MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017 51
May 03, 2017: MorphoSys Reports Solid First Quarter 2017 53
Corporate Communications 55
Sep 06, 2018: MorphoSys to be listed in MDAX 55
Jul 24, 2018: MorphoSys Appoints Jennifer Herron as President of MorphoSys US and Executive Vice President, Global Commercial 56
May 17, 2018: Annual General Meeting of MorphoSys Elects New Supervisory Board Members 57
Apr 10, 2018: MorphoSys Nominates New Candidates for Supervisory Board 58
Oct 30, 2017: Dr. Markus Enzelberger Appointed MorphoSyss Chief Scientific Officer 59
Product News 60
10/23/2017: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL 60
06/15/2018: MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018 61
05/18/2017: MorphoSys to Present Clinical Data on MOR-202 at Upcoming ASCO Annual Meeting 2017 62
05/17/2018: MorphoSys Announces Presentation of Clinical Data on CD38 antibody MOR202 at Upcoming EHA 2018 Conference 63
Product Approvals 64
Aug 08, 2018: MorphoSys and I-Mab Biopharma announce China IND submission of TJ202/MOR202 64
Clinical Trials 65
Jun 15, 2018: MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic Lymphocytic Leukemia at EHA 2018 Conference 65
May 17, 2018: MorphoSys Announces Presentation of Clinical Data on MOR208(Fc-engineered CD19 antibody) at Upcoming EHA 2018 Conference 67
Mar 13, 2018: MorphoSys Reports Updated Data from L-MIND Study of MOR208 plus Lenalidomide in Aggressive Lymphoma (r/r DLBCL) 68
Dec 11, 2017: MorphoSys Presents Clinical Data on MOR208 plus Lenalidomide in Aggressive Lymphoma (R/R DLBCL) at ASH 2017 Conference 70
Nov 02, 2017: MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017 72
Jun 05, 2017: MorphoSys Presents First Safety and Efficacy Data of MOR208 in Combination with Lenalidomide from a Phase 2 Study in DLBCL 73
May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers 75
May 18, 2017: MorphoSys to Present Clinical Data on MOR-208 at Upcoming ASCO Annual Meeting 2017 76
Feb 21, 2017: MorphoSyss Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107 77
Other Significant Developments 78
Sep 05, 2017: MorphoSys Presents Vision for Growth at its Capital Markets Day 78
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List Of Tables


MorphoSys AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Lanthio Pharma Raises US$6 Million In Series A Financing 13
MorphoSys Expands Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
Novartis Pharma Enters into Licensing Agreement with Galapagos and MorphoSys 21
I-Mab Biopharma Enters into Licensing Agreement with MorphoSys 23
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 25
MorphoSys Enters into Licensing Agreement with Merck Serono 27
MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 28
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 30
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 31
MorphoSys Raises USD239 Million in Public Offering of Shares 32
MorphoSys Raises USD124.3 Million in Private Placement of Shares 34
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 35
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 37
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys 38
MorphoSys AG, Key Competitors 39
MorphoSys AG, Key Employees 40
MorphoSys AG, Subsidiaries 41

List Of Figures


MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10

MorphoSys AG (MOR) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The companys pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used

USD 250 View Report

MorphoSys AG - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

MorphoSys AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe MorphoSys AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

MorphoSys AG (MOR) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The companys pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used

USD 250 View Report

MorphoSys AG - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

MorphoSys AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe MorphoSys AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available